Lanreotide vs Somatropin
Overview
Lanreotide and Somatropin are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Lanreotide and Somatropin across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Lanreotide | Somatropin | |
|---|---|---|
| Category | Hormonal | Hormonal |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 60-120 mg | 0.16-0.24 mg/kg/week (pediatric growth hormone deficiency); about 0.2 mg/day (adult growth hormone deficiency) |
| Frequency | every 4 weeks | daily subcutaneous injection |
| Reported benefits | suppression of excess growth hormone and IGF-1 in acromegaly, improved progression-free survival in GEP-NETs, reduction of carcinoid syndrome symptoms, inhibition of multiple GI and pancreatic hormones | In labeled use, somatropin increases linear growth in children with growth failure from growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, small size for gestational age and idiopathic short stature. In adults with diagnosed growth hormone deficiency, professional guidelines describe benefits in body composition, exercise capacity, skeletal integrity and quality-of-life measures, with the largest benefit in the most severely deficient patients. |
| Reported side effects | diarrhea, cholelithiasis, abdominal pain, hyperglycemia, bradycardia, injection site reactions, nausea, hypertension, headache, thyroid function decreases | Fluid retention, edema, arthralgia and carpal tunnel syndrome are common in adults. Labeled warnings include glucose intolerance and new-onset diabetes, intracranial hypertension, slipped capital femoral epiphysis and scoliosis progression in children, hypothyroidism, hypoadrenalism, pancreatitis and hypersensitivity reactions. |
Key differences
Primary use. Lanreotide is categorised under Hormonal, while Somatropin falls under Hormonal. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Lanreotide: FDA-approved. Somatropin: FDA-approved.
Dosing. Lanreotide is typically dosed at 60-120 mg (every 4 weeks). Somatropin is typically dosed at 0.16-0.24 mg/kg/week (pediatric growth hormone deficiency); about 0.2 mg/day (adult growth hormone deficiency) (daily subcutaneous injection).
Can you stack them?
Some protocols combine peptides, but stacking Lanreotide and Somatropin has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Lanreotide and Somatropin?
- Lanreotide and Somatropin are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status. Lanreotide is FDA-approved for one or more indications, whereas Somatropin is FDA-approved for one or more indications.
- What is Lanreotide used for?
- FDA-approved long-acting somatostatin analog for acromegaly, GEP-NETs, and carcinoid syndrome.
- What is Somatropin used for?
- Recombinant human growth hormone, FDA-approved for growth failure in children and growth hormone deficiency in adults.
- Can you take Lanreotide and Somatropin together?
- Some users combine peptides within a single protocol, but stacking Lanreotide and Somatropin has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Lanreotide or Somatropin FDA-approved?
- Lanreotide is FDA-approved for one or more indications. Somatropin is FDA-approved for one or more indications.
Read the full articles
- Lanreotide — full monograph: mechanism, research, dosing & references
- Somatropin — full monograph: mechanism, research, dosing & references